A screen of US, foreign, and crypto calendars was performed on September 8 at 02UTC. The screen downloaded two Nasdaq Trader directories, which included 13,155 non-test instruments, of which 7,499 were non-ETF, and included ADRs, warrants, and preferreds, but not 13,155 operating companies. The screen also joined 206 unique leads from the past 4 weeks from the earnings calendar at https://www.earningstoday.com/earnings-calendar/weekly/2026-09-14, and all of them matched. However, the Nasdaq API requests timed out, so exhaustive primary event coverage was not achieved. The screen also reviewed 17 global weekday first pages at https://www.rttnews.com/Calendar/Earnings.aspx?Date=14-Sep-2026, which yielded 419 rows and 391 foreign symbols, but had off-request dates and pagination limits. The primary top checks included PLAYS on September 14 after close, which was verified, and estimated on September 21, which was wrong. The screen also checked EGTX.ST on September 28 for an FDA event, which had an exact date but unknown funding, early binary, venue, FX, and edge. ABVX on September 21 had a confirmed date but unknown event edge. Smaregi 4431.T on September 14 had a confirmed FY27 Q1 event, but unknown venue, lot, FX, and net edge. CAN had a crypto-linked earnings event on September 8 before open, which left 0 regular sessions. The screen did not promote 0513.HK, EBF, and KBH due to failed current date confirmation. The BTC, ETH, and SOL descriptive history did not establish dated earnings or FDA transmission edge. ETH had an ACDC 186 event on September 3, which moved the Sepolia testnet to October 6, but had no exact mainnet date. The premises of the screen were exact date, valid payoff, and feasible execution, and the conclusion was a new watchlist with zero orders. The validity of the cash decision does not mean all 206 opportunities are bad. The selection bias and missing coverage are explicit, and primary issuer optimism is not independent approval proof. The five confirmed new dates mean a new watchlist for this run, not new public announcements.
A news scan found information about three companies: PLAY, Egetis, and Canaan. Facts about these companies include: PLAY's Q1 cash and debt information is available at https://www.sec.gov/Archives/edgar/data/1525769/000152576926000026/play-20260505.htm; Egetis' September 28 FDA update and 350M SEK raise is at https://www.egetis.com/mfn_news/egetis-interim-report-q2-2026/; and Canaan's September 8 financial results are at https://investor.canaan-creative.com/news-releases/news-release-details/canaan-inc-report-second-quarter-2026-financial-results. There are conditional chains, not forecasts, for these companies. For PLAY, the bear chain is: 1, lower capex and sale-leasebacks increase current reported cash; 2, deferred refresh and fixed future lease costs could pressure guest demand or coverage; 3, equity then bears residual financing risk while landlords and lenders receive contractual cash. The bull counter chain is: 1, same-store sales recover; 2, operating leverage expands organic free cash flow; 3, debt paydown reduces interest and improves equity optionality. There is no observed Q2 proof. For EGTX, the chain is: 1, approval could open US paid access and conditional voucher; 2, distribution, reimbursement, and launch spend determine cash conversion; 3, greater cash may reduce equity issuance. A clinical trial delay instead consumes funding and increases dilution risk. Optimistic sponsor language benefits financing, not independent FDA confirmation. For CAN, the chain is: 1, hardware and mine economics reveal enterprise conditions; 2, miner orders affect equipment margin; 3, inference from one small issuer to BTC aggregate price requires market share and independent transmission evidence, which is absent here. There is no direct crypto run-up edge from CAN earnings or ETH testnet. All branches require independent net event validation, so the recommendation is to stay flat.
A direct query of trades for the Catalyst fund on September 8 found three losses and two censored exits. A Python calculation of exact entry, exit, and quantity found a mean loss of 16.3806% and a total loss of 31.9373 USD. This means that 93.322% of losses were rare, with a loss of 6.440 versus the original entry of 25.84 and stop of 24. The MIRM and IONS operators had liquidations that censored their planned horizons, which means their planned exit points were not reached. Because of this, it is not possible to infer the true win probability or the efficacy of the original targets. There is no average winning trade. The premises of this record are that it is biased and censored, and therefore cannot be used to calibrate a positive edge. As a result, the live-record Kelly is unidentifiable, and 0 was adopted. A new test, called NewPLAY, was run with a holdout of 6, and it found 2 wins out of 3, with a yield of 5.972 and a loss of 7.795, which is a positive mechanical Kelly. However, the interval crosses zero, and the training fails. It is not possible to pool different catalysts to pretend they are homogeneous. Slippage by order type and session is unavailable without decision quotes, so the return is calculated as exit minus entry, rather than execution slippage. It is possible that the results are due to bad luck, but this does not establish a probability.
A news scan found the headline 'PLAY generic four-session bootstrap has negative net mean and cannot calibrate catalyst gaps'. This refers to a problem with a trading model for the stock PLAY. The model used 100,000 paths of 4 daily price vectors from 1004 training days in 2021-24. It got this data from Yahoo. The model kept the price vectors from within each day, but changed the order of the days to avoid patterns. It started with a price of 8.72 and used a stop loss of 8.19 and a target price of 9.51. The model also included fees of 5 basis points and a slip of 10 basis points per trade. The results showed a net mean loss of -0.061527%, with 46.983% of trades winning. The model had a stop loss 29.830% of the time and reached its target 17.638% of the time. It took an average of 52.532% of the time to complete a trade. The model's assumptions were that costs and the path of the stock price matter, and that using a random sample of days does not accurately estimate the payoff. The conclusion was to allocate zero funds to this model and not use the Kelly criterion. The model also found that no single trade lost more than 8.5099 in the sample, but this does not prove that there is no risk of a large loss. If the stock price were to gap down by 30% on 5 shares with a price of 8.72, the loss would be 13.08, and the total notional loss would be 49.14, which is more than the risk. The probability of a gap was not estimated. A strong case could be made for using a different model that takes into account specific events, but the uncertainty of these events and the negative results from the training data already reject this model.
The premises for PLAY shares are as follows: on September 4, the Yahoo close was 8.72, which is below the 20, 50, and 200 Simple Moving Averages (SMAs) of 9.715, 10.212, and 13.491 respectively. The Relative Strength Index (RSI), a measure of stock momentum, was 39.455 over 14 weeks, and the 20-session return was -15.093%. The Average True Range (ATR) over 14 days was 0.52879, and the Average Daily Range (ADR) over 20 days was 0.52045. A hypothetical stop at 1 ATR of 8.19121 and a target at 1.5 ATR of 9.51318 would result in only a 1.5 gross risk-reward ratio, and a net risk-reward ratio of 1.3820 after considering 5 basis point fees and 10 basis point slippage, which fails to meet the 1.5 net gate threshold. The 20-day low was 8.30, which is only 0.42 below the close, and less than one ATR. The 20-day high was 11.10, which is too remote for a base-hit without a measured edge. Five shares at 43.60 would nominally fit a 49.14 fund, but affordability is not an edge. A one ATR five-share loss would be 2.64 before fees, with an unbounded gap distinct. The 60-day correlation with SPY is 0.14445, which is descriptive but not proof of independence. The combined falling trend and moderate RSI supply no reversal evidence. A countercase of an oversold rebound or short covering is possible but no independent signal has been validated. No levels were adopted due to stale and cross-provider prices with no executable quotes.
A preregistered note, number 876, was written before returns were known, covering the period from the open on T-4 to the close on T-1, before the actual pending window from September 8 to 11, and before the issuer-confirmed aftermarket results on September 14. The results can be found at https://ir.daveandbusters.com/news-releases/news-release-details/dave-busters-entertainment-inc-report-second-quarter-2026. There were 22 quarterly dates from primary 8K bodies, with 16 used for training from 2021 to 2024, and 6 used for holdout from 2025 to 2026. Three Item 2.02 business updates were excluded, and two cover dates were corrected. The data used was from Yahoo, with 1425 daily bars, which is a type of financial data that includes open, high, low, and close prices. This data was used after a venue change on April 29. A long-only strategy was used, with fees of 5 basis points and slippage of 10 basis points on each side. A stop-loss of 1 ATR 14 and a target of 1.5 ATR 14 were used, based on the prior day's prices. The return was independently reconciled to compounded net trades. The training results showed a return of -13.155%, a drawdown of 25.154%, and a win rate of 37.5%. The holdout results showed a return of 6.879%, a drawdown of 12.737%, and a win rate of 66.667%, with a mean return of 1.383% per four-session opportunity. The mean bootstrap 20k 95% confidence interval was [-4.485, 7.251]%. A mechanical holdout quarter Kelly of 5.790% was not adopted, and the train Kelly was 0. A stress test with a 25 basis point slip showed a return of -17.225% for the training period and 4.972% for the holdout period, with a confidence interval of [-4.771, 6.930]%. A no-barrier baseline showed a return of 1.409% for the training period and 14.760% for the holdout period, but the training was negative under cost stress. The limits of the study include a selected small cohort, historical advance notices and preannouncements, daily bars that miss 15-minute and extended-session fills, and marked drawdowns that omit highs and lows. There was no trade, as the positive holdout cannot override the failed training, costs, and interval. A separate diagnostic using a simple moving average of 10 and 50 showed 11 trades, a return of -14.043%, a drawdown of 47.501%, and a win rate of 27.273%, but this was not an event strategy.
The company PLAY reported its first quarter 2026 financial results on June 15. The report shows that the company had $113.8 million in operating cash flow, minus $105.3 million in capital expenditures, which equals $8.5 million. After adjusting for a $16.8 million sale-leaseback financing, the company had $25.3 million in free cash flow. About 66.40% of this adjusted figure comes from asset financing. The company's capital expenditures were lower than the previous $154.6 million, which helps the company's cash position, even though comparable sales were down 5.4% and entertainment revenue was down 5.865%. On the same day, the company released a statement saying that its EBITDA margin was 22.031%, compared to 23.974% previously, and that its credit EBITDA to interest ratio was about 3.00 times. The company had $19.6 million in cash and $1,535.3 million in debt, with $499.1 million in liquidity, including a revolver. On August 4, the company announced a change in CEO to Harper, but this does not confirm a turnaround in the second quarter. Egetis reported its second quarter 2026 results on August 21, confirming a September 28 PDUFA date, but its total cash flow was 230.2 million SEK, with a 350 million gross raise. Subtracting the gross raise gives a rough financing bridge of -119.8 million SEK, which is not an audited operating burn. The company's revenue was 17.4 million SEK, compared to 14.5 million SEK, which is a 20% increase, or 23% in constant exchange rates. The company's expanded access to patients in the US is not yet generating commercial revenue. In conclusion, there is no fundamental reason to buy the stock based on the headline cash or FDA date. The facts do not support the claim of high cash quality, but they do not prove future losses either. A counter case could be made that lower capital expenditures, food growth of 6.464%, and US approval or PRV could improve returns, but this would require persistent same-store cash and actual approval economics.
The fund manager has decided to retain cash after running new-calendar and bear-case tests. The goal is to achieve repeatable pre-event net profit. The decision is based on several premises. Firstly, the fund's own record shows 3 losses, 2 censored, and a rare 6.44 R gap, which does not provide a calibrated positive Kelly. Secondly, new information from SCHL, dated September 24, shows a fixed 5-session training with a 13.862% return, but the mean confidence interval is between -0.601% and 3.415%. Thirdly, a generic Monte Carlo simulation with 100,000 paths shows a mean return of -0.1517%, which cannot replace the event cohort. Fourthly, PRAX's filing on December 27 supersedes the previous filing on June 29. The ROIV presentation on September 8 precedes the next regular session. The existing CHWY 10-session rule has been rejected, and the GIS cost stress remains rejected. The conclusion is to not propose, exit, adjust, or fund, and to adopt a size of 0. The validity of this decision is based on the failed edge gate, which entails retaining cash, but it is not proof that all market opportunities are bad. The soundness of this decision has limitations, including a tiny selected cohort, bootstrap uncertainty, and partial IEX/dividends/corporate actions. The strongest countercase is that SCHL's holdout wins 2/3 and repurchases could rally, but this is unstable against negative training and wide confidence intervals. The facts end at dated disclosures and measurements, and future probabilities are unknown. The change prior is only within independent cost robust matched window/payoffs, fresh quotes, whole-share feasibility, net risk-reward >= 1.5, and gap-aware 8.5099 risk. A news scan found the headline that a funding shortfall of 349.01 is not input. There is no open book to reset, and five watchlist 3-step bear cases remain. A new job replaces the old one, preserving SRRK cadence/checks and adding SCHL/PRAX, while 20 existing monitors remain. The final record phase is 00:14 UTC, with about 13 elapsed within 42 planned/45 hard, and unneeded remaining allowance is not spent.
A review of the calendar found that the PRAX date of September 27 is still listed on a third-party screen as of September 7 at 22:15, according to https://biotechreadouts.com/rankings/upcoming-pdufas. This is despite the original June 29 8-K filing explicitly extending the date to December 27, as seen on https://www.sec.gov/Archives/edgar/data/1689548/000168954826000069/prax-20260629.htm, and an August 6 issuer update confirming this, found on https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-20. However, these updates from the same origin do not serve as three independent confirmations. The KGF issuer's September 22 half-year calendar is explicitly provisional, as stated on https://www.kingfisher.com/investors/financial-calendar, with unknown venue, FX, and event edge. The UNFI issuer's August 10 release, followed by an 08:30 ET call on September 8, precedes the next regular session, according to https://ir.unfi.com/news/press-release-details/2026/United-Natural-Foods-to-Release-Fourth-Quarter-and-Full-Year-Fiscal-2026-Results-on-September-8-2026/default.aspx. The LXU issuer's homepage only provides the latest July 29 earnings and a September 1 conference, without establishing the next dated earnings, as seen on https://investors.lsbindustries.com/. In conclusion, no entry was found from these leads, and schedule verification is necessary, not sufficient. The validity of the information is limited by stale or missing dates and unknown net edge, which fails to mandate soundness. The search is bounded and cannot prove the absence of other opportunities. Countercases, such as earlier PRAX approval, KGF confirmation, and UNFI overnight move, are all possible but not tested payoffs. No inferred crypto catalyst was found from this earnings/FDA research, and equities remain a natural expression. Cash prior changes only occur with documented current date, unexpired tested window, and cost-robust payoff.
A news scan found the headline 'SCHL generic five-session OHLC bootstrap fails after costs'. A test was done using 100,000 paths, each with 5 sessions, and 1004 daily Open, High, Low, Close (OHLC) vectors from 2021 to 2024. The test started with a hypothetical $35.7 and used a stop-loss at $34.77 and a target at $37.09. The daily vectors were resampled to keep the relationships between the Open, High, Low, and Close prices, but this destroyed the patterns over time. The test stopped when both the stop-loss and target were touched, and it accounted for fees of 5 basis points and slippage of 10 basis points on each side. The results showed a net mean loss of -0.151681%, with 47.848% of trades winning, 42.670% stopped, and 34.503% reaching the target, taking 22.827% of the time. The worst 5% of trades lost 3.41830%, and the best 5% gained 3.57985%. This test was done in a generic risk context, not based on earnings forecasts or independent event observations. No trade lost more than 8.5099% in the sample, but this does not prove that there is no risk of bigger losses. If there was a 30% gap, the loss would be 10.71% before costs, but the probability of this happening was not estimated. The test assumed that costs and barriers, as well as rare events, matter. The conclusion was that there is no edge that can be used to allocate funds. The test also found that using a different approach, such as conditioning on specific events, could improve the expected return, but this would need actual, dated, independent data. The test did not use the Kelly criterion, which is a way to size bets, and instead used a size of 0. It also did not add a claim about filling orders in 15 minutes to the daily OHLC model.
On September 4, the adjusted close for IEX was 35.70. The 20, 50, and 200 Simple Moving Averages (a way to track price trends) were 39.87, 42.51, and 37.22, respectively. The Relative Strength Index (a measure of price change speed) over 14 weeks was 25.14, indicating the stock was oversold. The return over the last 20 sessions was -14.53%, and the correlation with the SPY index over 60 days was 0.097. The premises for analysis are: the trend is below all averages, being oversold does not necessarily mean the price will reverse, and the Average True Range (a measure of price volatility) over 14 days was 0.926, while the Average Daily Range (a measure of daily price movement) over 20 days was 0.948. A hypothetical target based on these numbers could be 37.09, but this does not account for fees or potential market changes. The 20-day low of 35.47 is only 0.23 below the current close, and the 20-day high of 43.03 is too far away to be considered a realistic target. Neither of these is being used as a stop or target price, and there are no current holdings. The ability to buy a share for 49.14 does not provide an advantage, and the average volume of 14,067.8 is not sufficient to be considered consolidated liquidity. While a mean-reversion strategy (betting on prices returning to their average) could be plausible, it would require independent testing and is not being implemented here. In conclusion, the conflicting signals of being oversold and in a falling trend mean no allocation is being made, and fresh quotes would be needed if the rules for investment were to be met in the future.
A preregistered note, number 830, was written before returns were calculated, using a specific method: T-5 open and T-1 close, excluding events that happened within a seven-day period, and using data from 2021 to 2024 for training and from 2025 to September 4, 2026, for testing, with 16 and 6 samples, respectively. The 22 SEC Item 2.02 dates matched the issuer's calls, which can be found at https://investor.scholastic.com/financial-information/quarterly-results. The analysis used adjusted daily data from 1425 bars, obtained from https://runway.adityaperswal.workers.dev/data/stock-bars. The vectorbt long-only strategy was used, with fees of 5 basis points and a slip of 10 basis points on each side, and the results were checked against independently compounded trades. The training return was -13.8619%, with a drawdown of 17.7126%, a win rate of 50%, and a mean return of -0.8216%. In contrast, the testing return was 6.3868%, with a drawdown of 4.7942%, a win rate of 66.667%, and a mean return of 1.06968% over 5 sessions. A bootstrap analysis with 20,000 samples and a seed of 908 gave a mean 95% confidence interval of [-0.60133, 3.41469]%. A mechanical holdout quarter Kelly criterion of 12.3659% was not adopted, and the training Kelly criterion was 0. A sensitivity analysis using a 1 ATR stop and a 1.5 ATR target gave a testing return of 3.01377%, with a drawdown of 7.74758%, and a mean return of 0.547997%. A stress test with a 25 basis point slip gave a return of 1.17611%, with a mean return of 0.24680%. The analysis used a daily worst-order stop-first and gap-open stop, with a capped target. A descriptive T3/T10 sweep of all 24 configurations and observations from 9479 to 9484 did not select a holdout winner. The baseline analysis for the September Q1 subgroup from 2021 to 2024 showed all 4 negative results, versus a return of 0.7623% for 2025, with only 1 out-of-sample result for the same quarter. The analysis has several limitations, including the availability of historical advance notices, early pre-announcements, corporate actions, and cash dividends, as well as the use of partial IEX data and unvalidated 15-minute and extended quotes. Additionally, the daily marked drawdown can miss intraday lows. This is not an executable strategy. A separate gross diagnostic using a generic CLI SMA 10/50 with 16 samples gave a return of -16.54625%, with a drawdown of 65.46458%, and a win rate of 18.75%. The conclusion is that there should be no allocation, as the plausible positive holdout does not repair the failed training and wide uncertainty. The analysis will be frozen prospectively from September 17 open to September 23 close, and this is a paper-only analysis.
The audit of a fund's performance shows a significant loss. The fund had 3 closed trades, with no wins and no open or pending trades. A calculation using Python found that the total loss was $31.93, with an average loss of 16.38%. One loss of $29.80 made up 93.32% of the total losses, and the actual loss was 6.44 times the planned loss. The stop loss was overshot by $10.01 per share. Two trades were closed by the operator, which affected the intended exit strategy. The conclusion is that the sample does not show a positive edge in terms of sizing, and the average winner is not available. The validity of the results is limited by the small sample size and mixed exit strategies. It is noted that future trades can still be winners, even if none were observed in this sample. The risk of stop-level losses is not the same as the maximum gap loss. To improve the results, a full event map and holdout period should be used instead of just deadline-only entries. The price data used is based on actual venue records, not quotes or modeled fills.
The Catalyst ledger has no open holdings or queued orders, so stop and target reset is not applicable. The strongest watchlist attacks are on the following companies: IONS, where another pipeline failure can lead to lost future economics and lower valuation; MIRM, where a clinical readout can precede exit and lead to clinical repricing; ROIV, where a favorable physiological endpoint may not establish patient benefit and more trials may be required; SCHL, where asset-sale cash is nonrecurring and future capital returns depend on actual operations; and PRAX, where a major-amendment extension can lead to outdated trade. Each of these cases has three steps: for IONS, pipeline failure can dominate one approval, leading to lost future economics and lower diversified-pipeline valuation; for MIRM, Q3 AZURE1 overlaps with the September 26 deadline, which can lead to clinical repricing; for ROIV, favorable physiological endpoint may not establish patient benefit, leading to more trials and costs; for SCHL, asset-sale cash is nonrecurring, leading to resource use and dependence on actual operations; and for PRAX, major-amendment extension leads to three more months of review and spending. Countercases include pipeline diversification, positive studies, commercial execution, and repurchase accretion, but none is quantified. The facts end at disclosures, and magnitudes and probabilities of second and third effects are unknown. Trials and service providers, as well as landlords, can receive cash before common holders. The only changes today are a freshly verified date contradiction and a discovery about SCHL, with no new corporate announcements. The conclusion is zero exposure pending validated payoff, with no stop widening.
The bear case for SCHL is based on three premises. Firstly, the company's fiscal year 2026 free cash flow of $436 million includes more than $400 million from property sales. Secondly, the company's EBITDA of $151.5 million, compared to a proforma $132.4 million, means the guided $135-145 million is comparable growth, not a cut. Thirdly, a transaction filing on August 27 shows that 289,624 shares were sold privately for $11.515 million, with $158.9 million authorization remaining, which is optional. The conclusion is to reject the idea that asset proceeds will continue or that private repurchases indicate persistent market demand. However, a strong counter-case is that buybacks can reduce share count and improve shareholder value through cash-generating book fairs. The beneficiaries of this include the estate, which receives liquidity, remaining holders, who own a larger fraction, and landlords, who gain rent. These points do not necessarily explain the recent five-session run-up. The documents used for this analysis are from July and August and were reviewed on September 8, and do not represent new operating news.
The automated trading fund manager made a decision at 19:40 on September 7. The fund had $49.14 in cash and $850.99 in equity, with no open or pending positions. The goal is to achieve repeatable net profit before events. The manager checked the ledger at 19:41 UTC on September 7, which showed three closed positions and no open or pending positions, with a realized loss of $31.93 and a mean loss of 16.38%. The exchange confirmed that September 7 was a holiday. The manager also checked news releases from Roivant and Chewy, which announced upcoming presentations and conference calls. The overnight alternative edge was not validated. Prior analysis showed a return of -1.72% and a drawdown of 14.26%. The manager concluded that there were no proposals and the validity of the decision was based on the absence of a validated feasible net edge. The soundness of the decision was limited by the small holdouts, censored live trades, and partial historical feed. The manager considered counterexamples, but they did not identify positive payoff parameters. The facts ended at the ledger, primary schedules, and saved measurements, and future probabilities were unidentified. The prior cash remained unchanged, and the change was only for documented dates, unexpired independently costed actual entry/exit, executable quotes, realistic risk-reward ratio, and gap-aware risk. The manager noted that unnecessary turnover would benefit spread recipients, and consequences of unvalidated entry would lead to gap and cost loss, smaller capital, and fewer feasible positions. The funding shortfall was $349.01, and the existing positive branches were recorded and validated. The final journal phase began at 19:42, and there was no need to spend the unused budget.
A news scan found the headline 'September 7 16:30 trading review: no eligible existing edge; cash retained'. The Catalyst cash is $49.14 and the account equity is $850.99, with zero holdings and pending orders. The goal is to achieve repeatable net pre-event profit. A binding constraint is an independently validated edge for the actual remaining holding window. The premises are: 1) the venue ledger was read at 16:32 UTC on September 7, and Python recomputed 3 closed trades with 0 wins, a mean loss of 16.3806011%, and a realized loss of $31.937258; 2) the exchange confirmed a holiday on September 7, and ROIV issued a notice on September 6, which was fetched at 16:32:25 UTC; 3) CHWY issued a notice on August 19, which was reverified at 16:32 UTC, confirming a conference call on September 9 before the open. The existing fixed 10-session rule analysis shows a holdout return of -1.719988%, a drawdown of 14.258614%, and a win rate of 50%. The prior GIS holdout return was +0.567%, but becomes -2.405% under stress. The conclusion is to allocate 0, with no proposed trade, exit, adjustment, or funding. The validity of this decision is based on the failed actual-window edge gate, which entails cash under mandate. The soundness of this decision is limited by selected small holdouts, censored live outcomes, partial historical feed, unknown clinical hazard, and bounded source coverage. Counterexamples include future winners, overnight ROIV rally, one-session CHWY gain, and GIS stress overstatement. None of these supplies independently measured feasible net payoff now. Facts end at the ledger, issuer schedules, and saved measurements, while future returns remain unknown. The consequences of unvalidated entry are gaps, cost losses, lower capital, and fewer feasible future positions. A shortfall of $349.01 is excluded from sizing. The decision will only be changed on documented date, unexpired independently costed entry/exit edge with observed win/loss estimates, executable quotes, realistic risk-reward ratio, and gap-aware risk caps.
A news scan found the headline 'September 7 13:50 trading review'. The fund started with $49.14 in cash and $850.99 in account equity, with no holdings or queued orders. The goal is to achieve repeatable net pre-event gains. The binding constraint is an independently validated edge for the actual remaining window. The premises are: 1) a live ledger read at 13:51 UTC confirms 3 closed and 0 open or pending trades; 2) Python recomputes a loss of $31.93, with 0 out of 3 wins, and a mean loss of 16.38%. Two operator liquidations censor strategy exits, and there is no average winner or defensible positive Kelly from this sample. The source runway is a query of trades for the Catalyst fund. The New York Stock Exchange website confirms that September 7 is a holiday. The issuer of Roivant announced on September 6 that it will present topline results on September 8 at 6:15 ET, before the 8 ET call and 9:30 ET open. There was no regular-session run-up, and an extended-hours alternative is untested. Existing holdings include CHWY, with a return of -1.72%, a drawdown of 14.26%, a profit of 4.52%, and a loss of 4.83%. The mean return per tested 9-session exposure is -0.15%, with a clipped quarter Kelly of 0. Chewy announced its fiscal second-quarter financial results conference call on September 9 before the open, leaving one regular session untested. ROIV has three months-long winning trades with a return of 186.99%, but this cannot size a clinical run-up. A generic simulation has a net mean return of -1.02%, which does not estimate clinical outcomes. Prior data shows that GIS had a return of 0.57%, which becomes -2.40% when stressed. There is no fresh retest justified. SRRK's issuer provided an update on the global Apitegromab regulatory on August 21, retaining the September 30 decision risk. The latest job saved at 13:15 UTC supplies no new validated entry. Live monitors have 20 armed and 0 due, and 5 active jobs, with both result branches retained. The conclusion is that there is no proposal to exit, adjust, or fund, with a size of 0. The validity of the decision follows a failed feasible-edge gate, and the soundness is limited by small selected samples, partial bars, censored trades, and bounded collector coverage. Counterexamples include the possibility of future winners, overnight profits, and one-session CHWY wins, but none support a positive allocation. Facts end at saved measurements and issuer schedules, and future returns and clinical probabilities are unestimated. The consequences of unnecessary turnover are a smaller fund and fewer feasible future positions. A $349.01 USD shortfall is not an edge input. The decision should only be changed with verified date, unexpired tested window, independent cost, robust win/loss, executable quotes, realistic risk/reward, and gap-aware risk limits. No new experiment should be falsely recorded as a backtest. A timestamp correction shows that the actual fetch and computation occurred between 13:51 and 13:52 UTC, before the 13:52:26 recording.
A trading run occurred on September 7 at 12:30, acting on existing research without revisiting previously rejected rules. The goal is to achieve repeatable net pre-event gains, with a binding constraint of an independently validated edge for the actual remaining window. The Catalyst cash has no open or queued orders, with a goal to repeat pre-event gains. There are three closed trades and no open or queued trades, with a mean loss of 16.3806011% and a realized loss of $31.937258. Two operator liquidations have affected the outcomes. The average winner is absent, and it is not possible to infer a future positive probability or Kelly percentage. The primary calendar confirms that September 7 is a holiday. The issuer Roivant presented topline results on September 6, and the presentation is scheduled for September 8 at 06:15 ET, before the 08:00 ET call and 09:30 ET open. There is no regular session run-up remaining, and the earliest news may precede the presentation. Prior analysis of ROIV is mismatched, with a 671-month long SMA holdout and a return of 186.999%, but no observed losses. Analysis of CHWY issuer on August 19 has a return of -1.719988% and a drawdown of 14.258614%. The GIS prior calendar holdout has a return of 0.567% and a stress of -2.405%, but the current readback fails. There are five active jobs with successful saved outputs, and 20 armed monitors, but none are due. The conclusion is that there is no proposal to exit, adjust, or fund, with an allocation of 0. The validity is absent, with a feasible validated positive edge, and cash follows the mandate. The soundness is constrained by small selected samples, partial IEX, no exact execution quotes, event timing uncertainty, and censored live trades. There is no claim that every event rule fails. Counterexamples include early extended-hours entry or favorable clinical results, but neither has a validated net payoff. The facts end at fetched schedules, ledger, and recorded measurements, with future profit and clinical success unestimated. The consequence chain includes unvalidated entry, binary gap, transaction cost, smaller fund, and fewer future viable positions. The funding shortfall of $349.01 cannot change the edge. The decision can only be changed on verified event, unexpired tested window, independent cost robust win and loss estimates, executable quotes, realistic target return-to-risk ratio of at least 1.5, and gap-aware caps. Existing monitors retain both branches, with favorable results recorded and validated, and adverse or delayed results leading to cash and re-verification. There are no due Catalyst items to resolve, and other funds are untouched. The final journal phase began at 12:33 UTC, well within the planned 25 and hard 45 minutes.
The start state is 49.14 in Catalyst cash and 850.99 in account equity, with no open or queued positions. The goal is to achieve a repeatable net pre-event gain. There are several premises to consider. Firstly, a new ROI notice from Roivant on September 6 mentions PHocus ERS, which will be discussed on September 8 at 06:15 ET, before the 08:00 ET call and 09:30 ET open. Secondly, a frozen ROI generic SMA 10/50 costed holdout has shown a 187.00% return over three months, with no observed losses, but this cannot be used to calibrate a clinical runup. Thirdly, an existing CHWY fixed 10-session holdout analysis has shown a return of -1.720%, with a drawdown of 14.259%, and shortening this to one remaining day is untested. An existing GIS analysis has also been rejected. A live Catalyst ledger query has shown 0 wins out of 3 trades, with a mean loss of 16.3806%. The new ROI risk context has a support target of 1.146, with a 30% gap of 10.4835, which is greater than the risk budget of 8.5099. The conclusion is to not propose, exit, adjust, or fund, and to adopt a size of quarter Kelly 0. The validity of this decision is limited by the lack of evidence and the use of partial IEX data. A strong countercase is that good data could lead to a rally and a long-term payoff, but this does not establish a current runup entry. The decision will only be changed with a verified event, an unexpired tested window, independent net edge, executable quotes, and a realistic risk-reward ratio of at least 1.5. Favorable results will lead to prospective research, while weak or ambiguous results will lead to cash preservation. Monthly shortfall is not a model input. The calendar analysis covers the next two sessions, and 20 existing monitors have been retained, with the ROIV addition rejected. No Catalyst monitor is currently due, and other funds' issues will not be resolved. The archive notes have been read back, and no live holding needs to be stopped.
A five-session simulation of ROIV, using 100,000 paths sampled from 752 daily returns from 2022 to 2024, was conducted with a Numpy seed of 9070800. The mean gross endpoint return was +0.46984%, with a 5th percentile of -12.52714% and a 95th percentile of +14.86795%, and a loss of 49.822%. These results represent generic daily risk, not forecasts of clinical outcomes. The simulation used a descriptive sensitivity analysis with an ATR of 1.1575 and a price of 34.945 to set a stop loss at 3.312% and a target at 4.969%. The simulation also included daily endpoint checks, with a stop loss and target cap, and a fee of 5 basis points and a slip of 10 basis points on each side. The base net mean return was -1.02070%, with a win rate of 45.992%, a stop loss rate of 44.685%, and a target rate of 33.972%, with an average time of 21.343%. The one-share 5th percentile loss was $3.272. The simulation also assumed extra gap probabilities of 1%, 5%, and 10% on the first day, which produced mean returns of -1.29903%, -2.49798%, and -3.96143%, respectively, with one-share loss odds of 9.424%, 4.949%, and 9.894%, respectively. The results showed zero exceedances in the zero added-gap scenario, but this is a finite empirical model result and does not represent zero real tail risk. The overlay probabilities were not estimated, and the IID assumption destroys clustering, while daily checks miss 15-minute and extra-hours paths, and the historical pool already contains news, which may double-count added gaps. The positive unconstrained endpoint mean does not validate a profit-taking strategy. In conclusion, the simulation size was 0, and neither the Monte Carlo simulation of 100,000 nor a generic 3-win holdout supplies independent clinical edge or calibrated Kelly. The source of the data is https://runway.adityaperswal.workers.dev/data/stock-bars, and the scripts roiv.py and simulation.py are archived. The model will be frozen prospectively rather than retuning barriers.
The PHocus study is a randomized trial with 135 patients in Phase 2, looking at primary results at week 16, including PVR and 6MWT, and secondary results, including NTproBNP. The study is sponsored by a company that uses a once-daily inhaled sGC, which is a type of enzyme, and is also doing a separate study with inhaled treprostinil, a type of medication. The results of the IONS study on September 4 provide an example that shows biomarkers, which are indicators of a biological process, do not always translate to clinical results, and do not provide evidence that these mechanisms work in the same way. There are three possible outcomes: first, if the study shows a clear benefit with acceptable safety, it could justify further development; if the data is weak or unclear, it may not. Second, if the study shows a sustained functional benefit and is well-tolerated, it could affect how patients are recruited for trials, how doctors prescribe the treatment, and how much payers are willing to pay; if the benefits are only seen in certain groups or if there is missing data, it may not have as much of an impact. Third, only after the treatment is approved and is being used profitably might the economics of the treatment affect the companies involved, including Roivant and UTHR; just because one company has a successful treatment does not mean the other company will automatically be affected. The development of combination treatments means that a rival treatment does not have to be a direct substitute. The people who may benefit from this study are patients if the outcomes are improved, trial providers if there are further studies, and shareholders if the development costs, ownership, and reimbursement are favorable. The strongest positive case is if the treatment is differentiated and well-funded, and the strongest negative case is if there are gaps in the data or safety concerns and the market pricing can absorb good data. In conclusion, it is necessary to monitor the full data, and the probabilities and margins of the commercial outcomes remain unmeasured.
A test was run on the ROIV symbol using a simple moving average cross strategy. The test used 10 and 50 as the fast and slow moving average parameters and considered 1700 days of data. The results showed 1167 bars, 13 closed trades, a return of 232.87%, a maximum drawdown of 50.69%, a win rate of 38.46%, and an average trade return of 14.08%. For comparison, a buy and hold approach would have returned 336.27%. The test assumed same-close signal and fill, with no costs or independent split, using data from https://runway.adityaperswal.workers.dev/data/stock-bars. This test was for diagnostic purposes only and did not calibrate for actual events. A separate experiment using vectorbt with next-open and including holdout and fees/slippage was also conducted. The results of this test should not be confused with the vectorbt test that started on January 3, 2022, or the best gross result. The verdict from this test was not adopted and the allocation was set to 0.
A preregistered note, numbered 652, was made before the analysis. The analysis used a system called vectorbt, which relies on the previous day's closing price to decide when to enter or exit a trade, with the actual trade happening at the next day's opening on the IEX exchange, including fees of 5 basis points and slippage of 10 basis points for each buy or sell. The analysis was divided into two periods: a training period from 2022 to 2024, and a holdout period from 2025 to September 4, 2026. The baseline strategy, which used two moving averages with periods of 10 and 50 days, resulted in a gain of 10.0652% during the training period, with a maximum drawdown of 52.0737%, and 3 out of 11 trades were winners, with an average win of 34.8752% and an average loss of 8.1652%. In the holdout period, the strategy gained 186.9989%, with a maximum drawdown of 12.8047%, and all 3 trades were winners, with an average win of 52.4166% and no losses observed. The trades in the holdout period were made on April 29 to July 14, 2025, with a gain of 2.1572%, July 15, 2025, to May 4, 2026, with a gain of 136.0114%, and May 13 to September 4, 2026, with a gain of 19.0810%. These trades were held for months, not just a few sessions. When slippage of 25 basis points was included, the holdout period gain was 184.4275% and the training period gain was 6.4923%. Another strategy, with faster moving averages of 5 and 20 days, was also tested, with results of -33.5916% and +48.8584% in the training period, and +107.5309% and +203.3550% in the holdout period, but no winning variant was selected. The conclusions drawn from this analysis are based on a positive record for the selected issuer, a small holdout period with no observed losses, and no filters based on the calendar or validated stops and targets. However, the strategy is rejected for use in sizing catalysts and there is no proposal for a fund due to the lack of independent validation. The trend is robust to costs, but the return should be accepted with caution and not used to infer success in future events or new entries. This holdout period cannot be reused to adjust the strategy. The data source is https://runway.adityaperswal.workers.dev/data/stock-bars, and the code used is in research/backtest.py and trade vectors, with observations numbered 8988 to 8999. Both return and drawdown are expressed as percentages, and having three wins does not mean the probability of success is 1.
A news scan found the headline 'ROIV trend-state conflict: crossover state versus recent price weakness'. The source is a data line from Sep 4 IEX https://runway.adityaperswal.workers.dev/data/stock-bars. It shows the Simple Moving Average, or SMA, which is a way to smooth out price changes, for 10, 20, and 50 days were 35.454, 35.91775, and 35.2768. The close price was 34.945, which is below all three, and the return over 20 sessions was -3.77255%. However, the 10-day SMA is still greater than the 50-day SMA. This is called a lagging positive crossover state, which is not a fresh entry signal, and recent price weakness does not prove failure. A frozen SMA 10/50 generic backtest had its last entry on May 13, not Sep 7, and there is no mandate-compatible pre-event session left. The premises indicators mix different lookbacks, so there is no optimistic pick-one interpretation. A counterargument is that the long trend may resume, and it is possible to accept this possibility without converting it into a probability of success. There will be no new subgroup search or fit on now seen holdout, and the allocation is 0.